Preset Prescriber Notes on Compounded Drugs: What FDA Found (2026)

FDA's September 18, 2026 warning letter to a 503A pharmacy read the prescriptions, not only the pharmacy. It found patient-specific "significant difference" statements repeated across many records, and said platforms offering preset menu choices for those statements could undermine them. For a telehealth business, your prescribing screen is now part of the evidence.

Those statements are what allow a pharmacy to compound a version of an approved drug for an individual patient. FDA read the repetition as a sign the statements were written in advance for prescribers to pick, not written for the patient in front of them.

What changed recently: FDA letters since our September review

We found no new compounding warning letters posted in October 2026 when searching FDA's warning letter and compounding action pages. Both letters above are dated in September; the September 18 letter was covered briefly in our earlier review and is examined in full here.

Does the split between pharmacy letters and brand letters still hold?

Yes. Both September letters went to the facility that makes the product, and both followed an on-site inspection, in October and November 2025, so each letter arrived about ten to eleven months after investigators were in the building. The brand letters of June 8, 2026 were decided from the sellers' own websites, one to three months after FDA reviewed them. Sterility and § 503A findings still go to the compounder after an inspection; marketing findings still go to the seller and are made from its pages.

What moved is the balance and the reach. For three months the published letters have all been facility letters. And the September 18 letter reached past the pharmacy's production records into the prescriptions themselves, which are the one document in a compounded-drug program that the telehealth platform, the prescriber and the pharmacy all touch.

What did FDA look at in the prescriptions?

Under section 503A, a pharmacy may not compound drugs that are essentially copies of a commercially available drug product regularly or in inordinate amounts. A compounded product with the same active ingredient is not treated as a copy when a prescriber has determined and documented a change that produces a significant difference for an identified individual patient. That documented determination is the hinge, and it is what FDA examined.

The letter describes three kinds of evidence, as FDA states them:

• Orders for the combination products at issue with no prescriber determination of a significant difference at all.
• Orders whose stated determinations appear to repeat across many records, which FDA reads as statements generated in advance for selection rather than written for a specific patient.
• The volume of particular products, which bears on whether copying happened regularly or in inordinate amounts.

The products named were tirzepatide with niacinamide and semaglutide with cyanocobalamin. FDA also wrote that third-party platforms that offer preset menu choices for a significant-difference statement could undermine the claim that those statements satisfy section 503A. A warning letter states FDA's position; it is not a court finding, and the recipient may respond.

What does FDA's guidance expect the prescriber's statement to say?

FDA's guidance on essentially-copy compounding under section 503A says the prescriber's determination should make clear that the prescriber identified the relevant change and the significant difference that change will produce for the patient. It is a clinical judgment about one person, recorded where the pharmacy can see it.

The same guidance lists pre-printed prescription pads that a prescriber can use to order a product that is essentially a copy as a factor suggesting the copying is regular or in inordinate amounts. A dropdown in a prescribing screen does the same job as a pre-printed pad: it puts the words in front of the prescriber before the patient is considered. FDA also does not treat a drug on its shortage list, or one that has been discontinued and is no longer marketed, as commercially available for this test, which is why the end of the GLP-1 shortages changed what pharmacies may make.

What should you check in your own prescribing flow and pharmacy?

Run these against your own program this month. Each one maps to evidence FDA described.

1. 1Open your prescribing screen for each compounded product and look for a preset list of reasons a compounded version is needed. If one exists, find out who wrote it and why.
2. 2Check whether a prescriber can submit an order for a compounded product without writing anything patient-specific. If the field is optional or pre-filled, it is not documenting a clinical judgment.
3. 3Pull twenty recent prescriptions for the same compounded product and compare the significant-difference statements word for word. Identical wording across different patients is the pattern FDA described.
4. 4For any additive, such as B12 or niacinamide, ask who decided it belongs in the product: the prescriber for a patient, or the program as part of the product design. The second is a business decision, and the guidance does not treat it as a clinical one.
5. 5Ask your pharmacy partner what it does when an order arrives without a significant-difference determination, or with one that matches the last fifty. Does it fill, query the prescriber, or decline?
6. 6Confirm where the prescriber's statement is stored, who can produce it, and how quickly, if your pharmacy partner is inspected and FDA asks for prescriptions written through your platform.
7. 7Read your marketing for the same product. If the additive is what you sell as making your program different, you have described a product design, which is the opposite of an individual clinical determination.

What this does not mean

It does not mean combination products are prohibited, and it does not mean templates are banned from clinical software. It means that when a compounded product depends on a prescriber's determination of a significant difference, the determination has to be the prescriber's, about the patient in front of them. The platform's job is to give the prescriber a place to record that judgment, not to supply it. Clinical decisions belong to independently licensed clinicians, and no platform, pharmacy or brand can make them on the prescriber's behalf.

If you run on a white-label platform, including MDLaunchr, ask to see exactly what the prescriber sees when ordering a compounded product, and treat any pre-written reason as something to remove rather than something to rely on.

Related reading: what FDA cited across the 2025 and 2026 GLP-1 letters, what FDA inspects at a compounding pharmacy, and what to ask yours, the FDA GLP-1 enforcement tracker and how to choose and verify a telehealth compounding pharmacy.